tRNA‐Derived Fragment tRF‐22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma
Advanced Science · 2026
DOI: 10.1002/advs.202505806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Ling Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Central Universities, Central Guiding Local Science and Technology Development Fund Projects.
Abstract (Originalsprache)
Small proportions of patients with esophageal squamous cell carcinoma (ESCC) benefit from immune checkpoint blockade therapy, making it urgent to identify factors that limit its effectiveness. It is found that tRF‐22 , a small RNA derived from tRNA GlnCTG/TTG , promotes an immunosuppressive tumor microenvironment. High tRF‐22 expression is associated with worse prognosis in ESCC. tRF‐22 shapes immunosuppression by increasing polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs) infiltration and suppressing CD8 + T cells. Mechanistically, it binds to Lys91 on hnRNPAB, inhibiting its ubiquitination by TRIM25, leading to the stabilization of hnRNPAB, which activates TGFB2 transcription. Accumulated TGFβ2 promotes MDSCs generation to drive immunosuppression in ESCC. Using tRF‐22 antagomir or TGFβ signaling blockade in combination with anti‐PD1 therapy enhances immune response and reduces tumor growth. Overall, a tRF‐22 –hnRNPAB–TGFβ2–PMN‐MDSCs–CD8 + T cell pathway is identified that drives immunosuppression and tumor growth. Targeting tRF‐22 may be a promising strategy to improve immunotherapy efficacy in ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
- Shandong Provincial Key Laboratory of Malignant Tumor Precision Treatment, Jinan, 250012, China.
- Shandong Provincial Engineering Research Center for Tumor Precision Treatment, Jinan, 250012, China.
- Department of Urology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
- Department of Organ Transplantation, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
- Department of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
ORCID-Profile: Ling Pan, Yufeng Cheng
Förderung
- National Natural Science Foundation of China
- Central Universities
- Central Guiding Local Science and Technology Development Fund Projects
- BeiGene Foundation
- Taishan Scholar Foundation of Shandong Province
- Natural Science Foundation of Shandong Province
Zitieren
APA
Pan, L., Qin, X., Gong, L., Liu, H., Cheng, B., Wang, J., Hu, Y., Zeng, L., Wang, Y., Song, Q., & Cheng, Y. (2026). tRNA‐Derived Fragment tRF‐22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202505806
Vancouver
Pan L, Qin X, Gong L, Liu H, Cheng B, Wang J, et al. tRNA‐Derived Fragment tRF‐22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma. Advanced Science. 2026. doi:10.1002/advs.202505806
BibTeX
@article{Pan2026,
author = {Pan, Ling and Qin, Xin and Gong, Li and Liu, Haining and Cheng, Bo and Wang, Jing and Hu, Yajie and Zeng, Lingxing and Wang, Yiping and Song, Qingxu and Cheng, Yufeng},
title = {tRNA‐Derived Fragment tRF‐22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202505806}
}
EUVIMED